The Food and Drug Administration has announced that they're cracking down on misleading drug company ads. The agency intends to send out uh thousands of warning letters and about a 100 cease and desist letters. Joining us now, FDA Commissioner Dr.. Marty McCary. We need some details uh doctor about about which one which whether we're talking about I don't know promoting benefits that aren't as significant as they do or leaving out side effects. I read about reading out side effects.When I watch ads at night ...

AstraZeneca CEO broke ranks with his pharmaceutical industry peers Tuesday, saying he was open to aligning drug prices globally https://t.co/eQHyxQ8wwF ...

Donald Trump's latest tariff missive focuses on the pharmaceutical industry, Nvidia expects to start shipping high-end chips to China soon and Kevin Hassett emerges as the frontrunner for the Fed job: Here is your Evening Briefing. https://t.co/3iO0dlhtF8 ...

Trade Policy on Pharmaceuticals - Tariffs of 200% will be imposed on pharmaceuticals brought into the country after a grace period of approximately one year to one and a half years [1] - The policy aims to address the departure of pharmaceutical companies to other locations [2] Trade Policy on Metals and Other Goods - Steel and aluminum tariffs are set at 50% [2] - Lumber tariffs have recently been implemented [2] - Copper tariffs are also set at 50% [2][3] - Tariffs have been implemented on cars [2] Expansion of Trade Policy - The company will announce policies related to pharmaceuticals, chips, and other significant sectors [2]

Obesity Drug Market & Competition - Amgen's once-monthly weight loss shot, Maritide, showed patients without type 2 diabetes losing an average of 20% of their body weight after one year, but with a high rate of side effects and discontinuations [1] - Eli Lilly appears to be leading the obesity drug race with a safe oral candidate and an injectable (amalin) that provides weight loss with less muscle mass loss [2] - Novo Nordisk is facing challenges with disappointing Kaggarma data, while Eli Lilly is presenting positive results [2] - Novo Nordisk currently holds 33% of the market share, but Eli Lilly's oral data looks promising [4] - The market may not be seeking a 25% weight loss if other options offer around 22% [5] Amgen's Valuation & Pharma Sector - Amgen's stock dropped almost 6% after disappointing results for its weight loss shot [1] - Amgen is trading at approximately 12-13 times next year's numbers, which may not be considered cheap given the current pharma multiples and revenue cliffs [7][8] - The average pharma multiple is around 10 [7] - Over 50% of revenue for companies like Merck and Bristol-Myers Squibb will disappear by the end of the decade [8] Biotech & M&A - Biotech has had a decent run, with potential catalysts for M&A activity [9] - Despite potential asset quality concerns, increased M&A activity is expected in the biotech sector due to revenue degradation at the pharma level [11] - Big Pharma companies need to pursue M&A, with Pfizer, having spent $60 billion since the pandemic, actively seeking more assets, potentially in the obesity area [12]